HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Drug evaluation: Lymphoseek - Neoprobe's sentinel lymph node imaging agent for use in cancer patients.

Abstract
Neoprobe, under license from the University of California San Diego Cancer Center, is developing 99mTc-DTPA-mannosyl-dextran (Lymphoseek) as a potential agent for imaging lymph nodes in patients undergoing treatment for breast cancer and melanoma. Phase II trials of Lymphoseek were initiated in mid 2006.
AuthorsTomas de Paulis
JournalCurrent opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 7 Issue 12 Pg. 1100-7 (Dec 2006) ISSN: 1472-4472 [Print] England
PMID17209528 (Publication Type: Journal Article, Review)
Chemical References
  • Contrast Media
Topics
  • Animals
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Contraindications
  • Contrast Media (adverse effects, pharmacokinetics)
  • Drug Evaluation, Preclinical
  • Humans
  • Sentinel Lymph Node Biopsy (methods)
  • Structure-Activity Relationship

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: